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Abstract
Background: Erythropoietin (EPO) improves cognition of human subjects in the clinical setting by as yet
unknown mechanisms. We developed a mouse model of robust cognitive improvement by EPO to obtain the first
clues of how EPO influences cognition, and how it may act on hippocampal neurons to modulate plasticity.
Results: We show here that a 3-week treatment of young mice with EPO enhances long-term potentiation (LTP),
a cellular correlate of learning processes in the CA1 region of the hippocampus. This treatment concomitantly
alters short-term synaptic plasticity and synaptic transmission, shifting the balance of excitatory and inhibitory
activity. These effects are accompanied by an improvement of hippocampus dependent memory, persisting for 3
weeks after termination of EPO injections, and are independent of changes in hematocrit. Networks of EPO-
treated primary hippocampal neurons develop lower overall spiking activity but enhanced bursting in discrete
neuronal assemblies. At the level of developing single neurons, EPO treatment reduces the typical increase in
excitatory synaptic transmission without changing the number of synaptic boutons, consistent with prolonged
functional silencing of synapses.
Conclusion:  We conclude that EPO improves hippocampus dependent memory by modulating plasticity,
synaptic connectivity and activity of memory-related neuronal networks. These mechanisms of action of EPO have
to be further exploited for treating neuropsychiatric diseases.
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Background
The hematopoietic growth factor erythropoietin (EPO)
has long been observed to exert beneficial effects on cog-
nition. Upon introduction of recombinant human EPO
into the clinic, cognitive improvement of patients with
chronic renal failure was noted during EPO treatment, but
attributed to its hematopoietic effects (for review see [1-
4]). Indeed, anemia after isovolemic hemodilution,
induced in healthy volunteers, impairs cognitive perform-
ance, which is completely restored by subsequent
autotransfusion [5].
However, the finding that EPO and its receptor (EPOR)
are expressed in the brain [6,7] (for review see also [1,3,8-
11]) led to the notion that EPO exerts direct, hematopoi-
esis-independent effects on the nervous system. The man-
ufacturing of EPO analogues with no hematopoietic but
potent neuroprotective properties, e.g. CEPO (car-
bamoylated EPO) [12], delivered proof-of-principle that
brain effects of EPO are not necessarily mediated by its
hematopoietic actions.
Beneficial effects of EPO on cognitive functioning have
been shown in different animal models of neuropsychiat-
ric diseases, e.g. on place navigation after global ischemia
or neurotrauma [13-17]. In a recent double-blind, pla-
cebo-controlled, proof-of-concept study in chronic schiz-
ophrenic patients, we showed that EPO improved
schizophrenia-relevant cognitive performance independ-
ently of its hematopoietic effects. In fact, EPO turned out
to be the first compound to exert a selective and lasting
beneficial effect on cognition in schizophrenia [18]. Sim-
ilarly, an increase in cognitive performance upon EPO in
patients with chronic progressive multiple sclerosis
occurred independently of changes in hemoglobin levels,
and persisted for months after termination of EPO treat-
ment [4,19].
Recently, the application of a single high intravenous dose
of EPO in healthy human volunteers was reported to
enhance the functional MRI-detectable hippocampus
response during memory retrieval 1 week later, before any
effect on hemoglobin was measured [20]. However, data
on hippocampus dependent memory in healthy human
subjects upon EPO are still missing. Altogether, little is
known about potential cognitive effects of EPO in healthy
individuals. Hengemihle et al. [21] reported that 19 weeks
of low-dose EPO treatment increased spatial memory per-
formance, and a conditioned learning task, taste aversion,
was enhanced by a single high-dose injection of EPO in
healthy mice [22].
In summary, the currently available data clearly indicate
that EPO can improve cognitive function of both rodents
and man by directly acting on the nervous system. To be
able to fully exploit this beneficial cognitive effect of EPO
for treatment of neuropsychiatric diseases, it is essential to
understand the cellular mechanisms of EPO action in
healthy brain, where interference of disease-related effects
can be excluded. Here, we systematically addressed this
problem. We developed a reliable, robust model for
improvement of cognition by EPO in healthy mice and
examined correlated effects of EPO on hippocampal syn-
aptic transmission and learning/memory-relevant synap-
tic plasticity. Further, we analysed effects of EPO on
cultured hippocampal neurons at network and single cell
levels. Our data indicate that EPO improves memory by
modulating synaptic connectivity of memory-related neu-
ronal networks within the hippocampus.
Results
EPO improves hippocampus dependent memory in 
healthy young mice
First goal of this study was to define an experimental con-
dition to test potential abilities of EPO to improve cogni-
tive functions. We used young (28 day old) male mice. In
our experimental set-up with 11 intra-peritoneal EPO ver-
sus placebo injections (5000 IU/kg) every other day for 3
weeks (Figure 1), EPO-treated mice showed significant
improvement of contextual memory in fear conditioning
1 week after the last injection, when tested 72 h after train-
ing in the same context (Figure 1, Exp. 1, Figure 2a). This
effect was still measurable 3 weeks after cessation of EPO
treatment but had disappeared after 4 weeks (Figure 1,
Exp. 2 and Exp. 3; Figure 2b, c). In contrast, EPO had no
effect on cued memory (Figure 2a–c; all P  > 0.05).
Whereas at 1 week after termination of treatment, hemat-
ocrit was still increased in EPO-treated mice (control
mice: 36.5 ± 0.84%, N = 8; EPO mice: 53.3 ± 1.34%, N =
10; P < 0.0001), there was no difference anymore between
groups at 3 weeks (control mice: 39.4 ± 1.19%, N = 14;
EPO mice: 40.8 ± 0.92%, N = 13; P = 0.338), indicating
that cognitive improvement and hematopoietic effects of
EPO are not directly related.
In two additional experiments, EPO was given only three
times either at the beginning or at the end of the 3-week
treatment period while the respective other eight injec-
tions consisted of placebo. In this setting, no improve-
ment in cognitive performance was obtained (data not
shown), suggesting that a certain amount of EPO treat-
ment is required for improving cognition.
The effect of EPO on hippocampus dependent (contex-
tual) memory was selective. There was no EPO effect on
anxiety, spontaneous activity, exploratory behavior, and
motor performance (Figure 2d–g; all P > 0.05). Time spent
in open arms of elevated plus maze (Figure 2d) and time
spent in the three different zones of open field was similar
in both groups (Figure 2e). Total distance traveled in openBMC Biology 2008, 6:37 http://www.biomedcentral.com/1741-7007/6/37
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field did not differ between groups nor did exploratory
activity in hole board test (Figure 2e, f). Over two days of
rota-rod testing, both groups did not differ in falling
latency (Figure 2g), indicating that motor performance
and motor learning were comparable. Taken together,
EPO treatment over 3 weeks leads to selective and long-
Experimental design of the in vivo studies Figure 1
Experimental design of the in vivo studies. The time line of behavioral testing and brain dissection is presented. EPO or 
placebo was injected every other day for 3 weeks (11 injections in total). Tests performed were elevated plus maze (EPM), 
open field (OF), hole board (HB), rota-rod (RR), and fear conditioning (FC), including training and testing 72 h later.
Basic behavior: 
EPM, OF, HB, RR
FC
training 
FC
testing
22 26 27 30
FC
training 
FC
testing
42 45 49 52
FC
training 
FC
testing
8 2 1 Days
Exp. 1
Exp. 2
Exp. 3
Exp. 4
Neuro-
physiology
Histology
EPO or placebo 
EPO or placebo 
EPO or placebo 
EPO or placebo 
EPO or placebo 
Exp. 5
Basic behavior: 
EPM, OF, HB, RR
FC
training 
FC
testing
FC
training 
FC
testing
FC
training 
FC
testing
Exp. 1
Exp. 2
Exp. 3
Exp. 4
Histology
EPO or placebo 
EPO or placebo 
EPO or placebo 
EPO or placebo 
EPO or placebo 
Exp. 5
Effects of EPO on hippocampus dependent memory Figure 2
Effects of EPO on hippocampus dependent memory. Percentage of freezing as a readout of memory function in fear 
conditioning shows significant effects upon EPO treatment in the contextual memory (context) task at 1 week (a) and 3 weeks 
(b), but no longer at 4 weeks (c) after the last EPO injection. Percentage of freezing measured during training (baseline), expo-
sition to the new context (pre-cue), and testing for cued memory (cue) is not different between the groups. No differences are 
seen in EPM (d), OF (e), HB (f), and RR (g). Mean ± S.E.M. N = 28 for experiment in (a) and N = 14 for all other experiments 
(b-g).
0
10
20
30
40
t
i
m
e
 
s
p
e
n
t
i
n
 
o
p
e
n
 
a
r
m
s
 
(
s
)
0
50
100
150
200
250
day 1 day 2
f
a
l
l
i
n
g
 
l
a
t
e
n
c
y
 
(
s
)
d o r - a t o R d r a o b   e l o H d l e i f   n e p O Elevated
plus maze
0.0
2.5
5.0
7.5
10.0
n
u
m
b
e
r
o
f
 
h
e
a
d
 
d
i
p
s
0
10
20
30
40
50
P=0.026
baseline context cue pre-cue
%
 
o
f
f
r
e
e
z
i
n
g
0
25
50
75
baseline context pre-cue cue
P=0.046
%
 
o
f
 
f
r
e
e
z
i
n
g
0
25
50
75
baseline context pre-cue cue
%
 
o
f
f
r
e
e
z
i
n
g
0
100
200
300
400
center periphery intermediate
t
i
m
e
 
(
s
)
0
10
20
30
40
50
60
d
i
s
t
a
n
c
e
 
(
m
)
Control
EPO
Fear conditioning 3 weeks
after the last injection
Fear conditioning 4 weeks
after the last injection
a
d
c b
fg e
Fear conditioning 1 week
after the last injectionBMC Biology 2008, 6:37 http://www.biomedcentral.com/1741-7007/6/37
Page 4 of 16
(page number not for citation purposes)
lasting improvement of hippocampus dependent (but not
of global) memory in healthy mice, independent of
hematopoietic effects.
Synaptic plasticity is significantly increased at Schaffer 
collateral CA1 synapses in EPO-treated mice
One likely explanation for the selective improvement of
contextual memory would be a direct influence of EPO on
synaptic plasticity in the hippocampus. We therefore
investigated the effect of EPO in acute hippocampal slices
from mice at 1 week after the last injection (Figure 1, Exp.
4). We first performed extra-cellular recordings of field
excitatory postsynaptic potentials (fEPSPs). Input-output
curves were obtained by evoking responses from stratum
radiatum of the CA1 region after stimulation of Schaffer
collaterals with increasing stimulation strengths (Figure
3a, b). Average of fEPSP slopes (Figure 3b) between stim-
ulus intensities of 110–150 μA from all slices yielded no
difference between control and EPO groups. Half-maxi-
mal stimulation strength was also comparable (Figure 3b,
inset). Thus, EPO treatment for 3 weeks, followed by a
treatment-free week, does not alter basal excitability.
Neurophysiology of acute hippocampal slices: Extracellular recordings Figure 3
Neurophysiology of acute hippocampal slices: Extracellular recordings. (a-b) Input-output relation is not altered at 
Schaffer collateral-CA1 synapses in EPO-treated mice. (a) Sample recordings at 50% of maximal response (average of four 
traces) are shown for control and EPO-treated mice. (b) Input-output curve as a measure of baseline excitatory synaptic trans-
mission: fEPSP slope, plotted against the stimulation strength, is not altered in EPO-treated mice compared to control (P = 
0.3094). Inset: Half maximal stimulation strengths are not significantly different. (c-d) Paired-pulse facilitation is enhanced in 
EPO-treated mice. (c) Sample traces are presented. (d) Paired-pulse ratio (fEPSP slope for the second stimulus/fEPSP slope for 
the first stimulus) at inter-stimulus intervals of 25–150 ms is significantly greater in EPO-treated mice. (e-h) Increased LTP at 
Schaffer collateral CA1 synapses in EPO-treated mice. (e) Sample traces of responses are shown before and after high fre-
quency stimulation (HFS; 3 × 100 Hz for 1 s each, 20 s interval). (f) Long-term potentiation elicited by HFS: Slopes of fEPSP are 
normalized to baseline and plotted against time. Time-point 0 represents application of HFS. (g) Magnitude of STP, determined 
as maximal responses within 1 min after HFS, is significantly greater in EPO-treated mice. (h) Magnitude of LTP, determined as 
responses between 50 and 60 min after HFS, is significantly greater in EPO-treated mice. (i-l) Increased STD at Schaffer collat-
eral-CA1 synapses in EPO-treated mice. (i) Sample traces of responses are shown before and after low frequency stimulation 
(LFS; 1 Hz for 900 stimulations). (j) Long-term depression elicited by LFS: Slopes of fEPSP are normalized to baseline and plot-
ted against time. Time 0 represents application of LFS. (k) Magnitude of STD, determined as maximal responses within 1 min 
after LFS, is significantly greater in EPO-treated mice. (l) Magnitude of LTD, determined as responses between 50 and 60 min 
after LFS, is not significantly changed in EPO-treated mice (P = 0.0869).BMC Biology 2008, 6:37 http://www.biomedcentral.com/1741-7007/6/37
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We then measured paired-pulse facilitation (PPF), the
shortest form of plasticity at many synapses [31], at differ-
ent inter-stimulus intervals (25–200 ms) in the Schaffer
collateral CA1 pathway as ratio of the second fEPSP slope
to the first fEPSP slope. Slices from EPO mice showed sig-
nificantly enhanced paired-pulse facilitation at inter-stim-
ulus intervals 25–150 ms (Figure 3c, d). Next, the effect of
EPO on short-term potentiation (STP) and long-term
potentiation (LTP) at the Schaffer collateral CA1 pathway
was examined (Figure 3e–h). The magnitude of STP was
defined as the maximal responses within the first minutes
after induction by a train of 100 Hz stimuli. STP was sig-
nificantly enhanced in slices of EPO mice compared to
control (Figure 3f, g). Furthermore, the magnitude of LTP,
determined as the average of responses between 50 and 60
min after induction by a train of 100 Hz stimuli, was also
enhanced in slices of EPO mice compared to control (Fig-
ure 3f, h).
Another form of synaptic plasticity is long-term depres-
sion (LTD). We determined the effect of EPO treatment on
short-term depression (STD) and LTD at Schaffer collat-
eral CA1 pathway (Figure 3i–l). Magnitude of STD was
defined as maximal responses within the first minutes
after induction by a train of 900 stimuli (1 Hz). We found
that STD was significantly enhanced in slices of EPO mice
compared to control (Figure 3j, k). On the other hand, the
magnitude of LTD, determined as average of responses
between 50 and 60 min after induction by a train of 900
stimuli (1 Hz), was not significantly different in slices of
EPO mice compared to control (Figure 3j, l). Collectively,
these data show that EPO modulates synaptic plasticity
and LTP in the hippocampus, but has no significant effect
on LTD.
EPO differentially influences inhibitory and excitatory 
synaptic transmission in the Schaffer collateral CA1 
pathway
To study cellular mechanisms of EPO action, we per-
formed whole-cell patch-clamp recordings on CA1
pyramidal neurons in acute hippocampal slices from mice
at 1 week after the last injection (Figure 1, Exp. 4; Figure
4a–f). Compared to control mice, the frequency of spon-
taneous inhibitory postsynaptic currents (sIPSCs) in CA1
pyramidal neurons of EPO mice was increased, while the
amplitude of sIPSCs was unchanged (Figure 4b, c). In con-
Neurophysiology of acute hippocampal slices: Intracellular recordings Figure 4
Neurophysiology of acute hippocampal slices: Intracellular recordings. (a-c) EPO enhances inhibitory transmission. 
(a) Representative recordings of spontaneous, pharmacologically isolated inhibitory postsynaptic currents (sIPSCs) from CA1 
neurons. (b) Averaged amplitude of sIPSCs is not significantly altered in EPO-treated mice (N = 6 neurons/5 mice) compared 
to control (N = 4 neurons/4 mice; P = 0.0869). (c) Averaged frequency of sIPSCs is significantly enhanced in EPO-treated mice 
(N = 6 neurons/5 mice) compared to control (N = 4 neurons/4 mice). (d-f) EPO decreases excitatory transmission. (d) Repre-
sentative recordings of spontaneous, pharmacologically isolated excitatory postsynaptic currents (sEPSCs) from CA1 neurons. 
(e) Averaged amplitude of sEPSCs is significantly decreased in EPO-treated mice (N = 4 neurons/4 mice) compared to control 
(N = 4 neurons/3 mice). (f) averaged frequency of sEPSCs is significantly decreased in EPO-treated mice (N = 4 neurons/4 
mice) compared to control (N = 4 neurons/3 mice).
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trast, EPO led to a significant decrease of both amplitude
and frequency of spontaneous excitatory postsynaptic cur-
rents (sEPSCs) in CA1 pyramidal neurons (Figure 4e, f).
Importantly, there were no significant differences in input
resistance or basic noise level between neurons of control
and EPO mice (data not shown). Thus, EPO modulates
inhibitory and excitatory synaptic transmission inversely.
We wondered whether the neurophysiological changes
found in hippocampal slices upon EPO treatment would
be due to alterations in total volume or synapse counts in
the involved areas, CA1 and CA3. Neither volume of CA1
(control: 3.97 ± 0.11 mm3, N = 9; EPO: 4.02 ± 0.16 mm3,
N = 10; P = 0.81) nor CA3 (control: 3.29 ± 0.21 mm3, N
= 8; EPO: 3.56 ± 0.25 mm3, N = 10; P = 0.42), nor total
hippocampal volume (control: 9.54 ± 0.34 mm3, N = 8,
versus EPO: 9.74 ± 0.39 mm3, N = 10; P = 0.71) were sig-
nificantly different. Moreover, density of synaptic bou-
tons in CA1 (control: 1.28 ± 0.08 boutons/μm2, N = 7;
EPO: 1.32 ± 0.11 boutons/μm2, N = 9; P = 0.75) and CA3
(control: 0.71 ± 0.13 boutons/μm2, N = 7; EPO: 0.78 ±
0.08 boutons/μm2, N = 9; P = 0.61) was not changed.
Quantitative RT PCR and/or Western blotting using
extracts of whole hippocampus did not reveal differences
in expression of synaptic proteins (synapsin1, synapto-
physin), postsynaptic receptor proteins (GABAA1,2,3,4;
NMDAR1, R2A, R2B) or BDNF, as potential mediating
neurotrophic factor [20,32] (data not shown).
EPO modulates spontaneous electrical network activity in 
primary hippocampal neurons as determined by multi-
electrode measurements
Above data demonstrated distinct and long-lasting effects
of temporary high-dose EPO treatment on hippocampus
dependent memory and synaptic plasticity in hippocam-
pal slice preparations. As the peritoneal applications of
EPO might have caused indirect effects on nerve cells, we
next studied primary hippocampal cultures. We tested
whether chronic EPO treatment, extending from an
advanced developmental stage (day 5 in culture) to over 3
weeks leads to alterations in spontaneous neuronal net-
work activity, and whether such changes would persist
upon cessation of EPO treatment.
First, our long-term cultures were characterized regarding
morphological appearance (Figure 5a), total cell numbers
(day 10: control: 202.4 ± 11.03, N = 6; EPO: 191.0 ±
8.834, N = 6; P = 0.436; day 30: control: 147.9 ± 26.26, N
= 6; EPO: 152.8 ± 27.87, N = 6; P = 0.902), and relative
contribution of different cell types (Figure 5b). In none of
these parameters were differences upon EPO found at
days 10 or 30 in culture. Also, quantitative RT PCR and
protein expression, determined by Western blotting,
failed to uncover differences in synapsin1 or synapto-
physin gene expression at any of the time points tested
(days 8, 14, and 30). Thus, EPO treatment did not cause
changes in morphology under our culture conditions.
Figure 5c illustrates primary hippocampal neurons grown
on multi-electrode array (MEA) dishes. Group statistics
for spontaneous electrical activity in the MEAs are pre-
sented in Figures 5d and 5e, contrasting silencing
(number of channels with < 5 spikes per 2 min) and burst-
ing behavior (percentage of strongly bursting channels of
all active channels, with strongly bursting channels
defined as channels with a coefficient of variation > 2.6).
With increasing age and maturation of culture, the
number of silent channels decreased in control MEAs, as
expected (Figure 5d). This was not the case in EPO cul-
tures. Whereas during the treatment phase itself, cultures
behaved largely similarly (weeks 3 and 4 with P = 0.41
and P = 0.18, respectively), differences became obvious at
later time points (weeks 5 through 7 with P = 0.047, P =
0.0043 and P = 0.0043, respectively). This indicates that
temporary EPO treatment causes a significant number of
channels to remain silent for an extended period after ces-
sation of EPO addition to cultures.
The bursting channel analysis, presented in Figure 5e,
showed that EPO provoked a consistently higher number
of bursts in hippocampal cultures, obvious only at late
time points, i.e. 2–3 weeks after termination of EPO treat-
ment. This effect (expressed as percentage of all active
channels in order to exclude the influence of silencing)
was less pronounced as compared to the silencing effect of
EPO. Whereas medians at week 6 were not yet signifi-
cantly different (P = 0.10), difference reached significance
at week 7 (P = 0.019). Together, the trend of weeks 6 and
7, when compared with the almost equal-bursting situa-
tion at week 5 (P = 0.70), confirms that bursting tends to
increase as a late consequence of transient EPO treatment,
in parallel with the persistently high percentage of silent
channels.
Reduction of synaptic vesicle priming and transmitter 
release in the EPO pre-treated neurons
The finding of long-lasting EPO-induced dampening of
spontaneous electrical activity in our primary hippocam-
pal cultures together with a selective increase in bursting
activity following EPO treatment prompted us to test indi-
vidual neurons. We examined the effect of EPO in hippoc-
ampal autaptic cultures [30], to directly assess the EPO
effect on presynaptic transmitter vesicle exocytosis and
postsynaptic receptor responses. Autaptic neurons are
neurons forming synapses on themselves, making electro-
physiological stimulation and respective effect determina-
tion (recording) simple. Cultures were treated with EPO
(0.3 IU/ml = 10-10M) or the respective buffer solution
only once at day 7 and then measured from days 9 to 14.
There were no morphological differences detectable uponBMC Biology 2008, 6:37 http://www.biomedcentral.com/1741-7007/6/37
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treatment, and sizes of somata as estimated by measure-
ment of whole cell capacitance were comparable between
EPO-treated and control neurons (control neurons: 49.61
± 2.75pF, N = 54; EPO neurons: 46.0 ± 2.73pF, N = 49; P
= 0.355).
Evoked excitatory postsynaptic current (EPSC) ampli-
tudes in EPO-treated neurons were reduced to about 60%
of control (Figure 6a), confirming the data obtained in
acute slices (Figure 4e). This EPSC reduction was due to a
parallel reduction in pool size of fusion-competent and
primed (readily releasable) vesicles, whose release can be
triggered by hypertonic solution containing 0.5 M sucrose
[33]. EPO neurons showed a drastic reduction in readily
releasable pool size to 60% of control (Figure 6b). Vesic-
ular release probability, calculated by dividing the charge
transfer during a single EPSC by the charge transfer meas-
ured during readily releasable pool release, was not differ-
ent between control and EPO neurons (P = 0.4116; Figure
6c). To test whether the reduction of neurotransmitter
release in EPO neurons can be attributed to a reduction in
quantal size, we analysed miniature EPSCs (mEPSC).
mEPSC frequency in EPO neurons was reduced to about
50% of control, without changes in mEPSC amplitudes (P
= 0.5817; Figure 6d, e). The lack of a difference in NMDA/
AMPA ratio indicates a comparable maturation state of
cultures (Figure 6f). Using trains of action potentials we
estimated the efficiency of Ca2+ triggered release. In gen-
eral, vesicular release probability closely correlates with
depression and steady-state level of EPSC amplitude sizes
during high frequency stimulation. We therefore moni-
tored EPSC amplitudes during 50 consecutive action
Multi-electrode array studies of primary hippocampal neurons Figure 5
Multi-electrode array studies of primary hippocampal neurons. (a-b) Characterization of the cultures. (a) Immunocy-
tochemical staining demonstrates maturation of cellular networks from day 10 to day 30. Propidium iodide staining of all nuclei 
(red), visualization of cell types by MAP-2 (mature neurons) or GFAP (astrocytes) staining (green), as well as merged pictures 
are presented (scale bar = 100 μm). (b) Cellular composition of networks remains stable over time and is not altered by EPO 
treatment (0.3 IU/ml every other day) from day 5 through 25 in culture (Mean ± S.E.M. of N = 3 independent cultures per time 
point). (c) Demonstration of primary hippocampal neurons grown on multi-electrode array dishes, containing 60 electrodes/
dish. (d-e) Spontaneous electrical activity of primary hippocampal neuronal networks in culture is measured daily from week 3 
through week 7. Group statistics of the multi-electrode array recordings over each week show significant dissociation over 
time of EPO versus control cultures. (d) Silencing group statistics reveal a global decrease of channels with low activity in con-
trol cultures that cannot be observed in EPO-treated cultures. (e) Bursting group statistics show that the percentage of 
strongly bursting channels increases in the EPO group after termination of treatment. Medians ± S.E.M. presented of N = 7 
independent cultures. P values are given in the text.
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potentials applied at a frequency of 10 Hz. EPO and con-
trol neurons showed regular moderate depression of EPSC
amplitudes (control: about 38%, N = 60; EPO: depression
at the end of train about 35%, N = 60, Figure 6g). Stability
of EPSC amplitudes during short-term plasticity, which is
due to the quantitative balance between priming of synap-
tic vesicles and number of vesicles released, was identical
in presynaptic terminals of each group.
Thus, EPO treatment of autaptic neurons leads to a reduc-
tion in the amount of primed vesicles or number of syn-
apses without altering efficiency of vesicle fusion and
vesicle dynamics. Counting of synaptic boutons per neu-
ron revealed a considerable increase from day 9 to day 14
in culture, which, however, was not changed by EPO (Fig-
ure 6h). Therefore, EPO is likely to reduce the number of
active synapses without altering total synapse number.
Discussion
We show that young mice, systemically treated with EPO
for 3 weeks, exhibit improved hippocampus-associated
memory. This selective improvement was maintained for
an EPO treatment-free period of another 3 weeks, and was
unrelated to increases in hematocrit, indicating a hemat-
opoiesis-independent effect of EPO on neuroplasticity.
The long-lasting effect of EPO on neuroplasticity was con-
firmed by analyses of paired-pulse facilitation, STP, LTP
and STD, as well as of spontaneous synaptic activity in
acute hippocampal slices, obtained from EPO-treated
mice at the time point of EPO-induced enhancement of
memory. MEA recordings of neuronal assemblies in vitro
and the analysis of individual autaptic hippocampal neu-
rons did not only confirm direct effects of EPO on neural
cells, but also reveal potential mechanisms of action: EPO
leads to a reduction in the amount of primed vesicles
without altering number of synapses or efficiency of vesi-
cle fusion and vesicle dynamics. Thus, most likely via
increasing the proportion of silent synapses, EPO reduces
overall spiking activity of neurons and enhances bursting
efficiency of selected neuronal networks. Most of these
data are consistent with EPO shifting the balance between
excitatory and inhibitory transmission (i.e. functionally
silencing a subset of excitatory presynaptic sites and
increasing activity of inhibitory neurons), although other
mechanisms cannot be entirely excluded at this point.
In humans, improvement of cognitive function upon
treatment with EPO has only been demonstrated in dis-
Autaptic hippocampal neuronal cultures Figure 6
Autaptic hippocampal neuronal cultures. (a-g) Whole-cell electrophysiological recordings from single hippocampal neu-
rons treated with either EPO (0.3 IU/ml) or control (diluent only) on day 7 and measured from day 9–14. Results indicate a 
reduction in the amount of primed vesicles without altering efficiency of vesicle fusion and vesicle dynamics. Mean ± S.E.M. pre-
sented. N = 40–60. (h) Analysing the number of synaptic boutons upon immunocytochemical staining for synapsin1 revealed an 
almost identical increase of boutons over time in EPO-treated and control neurons. Performed at 40x. Cumulative distribution 
over days 9–14. N = 100–120.
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ease states [18,19,34], i.e. in conditions of reduced/dis-
turbed baseline performance. Exploring healthy
individuals has therefore been a risky endeavour,
although, if successful, promised to deliver a cleaner pic-
ture of mechanisms of EPO action, lacking interference
with potential disease variables. Similar to what is
observed with endurance and muscular performance dur-
ing doping [35], where healthy individuals show dramatic
improvement, we found significant memory effects in
healthy mice. EPO-treated compared to placebo-treated
mice had a significantly longer duration of freezing, as
readout of memory function, during a contextual memory
test that is known to be critically dependent on the hip-
pocampus [36,37]. This finding implies that in healthy
individuals the potential cognitive capacity is not fully
exhausted. Although results were obtained in mice, the
work of Miskowiak and colleagues [20] may indicate that
respective effects can be expected in healthy humans.
Similar to the findings of Miskowiak et al. [20], the effect
of EPO on hippocampal functions was measurable at 1
week after injection. In our setting, treatment for 3 weeks
(11 injections) was necessary to obtain positive results on
cognitive performance. Reduced to only three injections,
no measurable effect on the behavioral readout of hippoc-
ampal functions was obtained. Healthy humans showed
increased hippocampal response (perfusion equivalent)
in functional magnetic resonance imaging upon memory
retrieval already 1 week after a single EPO dose. However,
effects on memory function were also not detectable after
this single dose [20]. In other words, for cognitive
improvement (and not only for increase in perfusion),
more than a single injection is needed also in humans. In
both studies, the hematocrit seems irrelevant. In the
human study, a single dose of EPO had not changed the
hematocrit after 1 week [20]. In our study, the hematocrit
was already back to control levels when we still observed
a significant effect on cognition, and direct effects of EPO
on synaptic plasticity were found in hippocampal cul-
tures.
The persistent effect of EPO on cognition, lasting for over
3 weeks after cessation of treatment, indicates alterations
in neuroplasticity induced by EPO that do not require its
continuous presence. Interestingly, our studies in MS
patients showed beneficial effects of EPO on motor func-
tion, which lasted for up to 6 months after termination of
a 6-months treatment [19]. In search for a mechanism
explaining the lasting influence of EPO on hippocampus-
associated memory, we detected pronounced EPO effects
on short-term and long-term plasticity, as well as on exci-
tatory and inhibitory synaptic transmission in the Schaffer
collateral CA1 pathway. These electrophysiological
parameters of plasticity have been associated with learn-
ing and memory [38-40].
Further exploring mechanisms of action of EPO, we
employed multi-electrode arrays to study network activity
in primary hippocampal cultures. We found that chronic
application of EPO in a fashion similar to our in vivo
approach resulted in persistence of a large population of
silent channels but enhanced bursting efficiency of dis-
crete neuronal circuits. In acute hippocampal slices as well
as autaptic hippocampal cultures, excitatory synaptic
transmission was decreased upon EPO treatment, whereas
inhibitory synaptic transmission was increased. In line
with these data, EPO-mediated inhibition of glutamate
release has been reported for cerebellar granule cells [41].
Together, these findings may point to an enhanced lateral
inhibition within the hippocampal neuronal network by
EPO, leading to amplification of active synaptic connec-
tions. A concurrent suppression of surrounding synapses
by EPO, consistent with lasting functional silencing, may
ultimately achieve segregation/refinement of neuronal
networks (for review see [42]). Interestingly, signal trans-
duction pathways known to be activated in hippocampal
neurons by EPO, include PI3K-PKB/Akt1 and RAS-MAPK
[43,44]. Both, the MAPK-mediated pathway [45-47] and
PI3K have been linked to LTP [48,49].
Conclusion
Although not providing complete mechanistic insight at
this point, our data indicate that the selective enhancing
effect of EPO on hippocampus dependent memory is
mediated via profound changes in neuroplasticity. These
plastic changes, in turn, may be based on a more efficient
bursting activity of selected synapses together with persist-
ent silencing of other synapses.
Methods
Animals
All experiments were approved by and conducted in
accordance with the regulations of the local Animal Care
and Use Committee. For all experiments, young (28 days
old) C57/Bl6 male mice were used. They were housed in
groups of five in standard plastic cages and maintained in
a temperature-controlled environment (21 ± 2°C) on a 12
h light/dark cycle with food and water available ad libi-
tum.
Drug treatment
For experiments 1–5, mice were injected intra-peritoneal
with EPO (Epoetin-alpha, Janssen-Cilag, Neuss, Ger-
many, 5 IU/g in 0.01 ml) or placebo (diluent for EPO,
0.01 ml/g) every other day for 3 weeks (11 injections in
total). Two additional groups of mice received only three
injections of EPO or placebo either at the beginning or at
the end of the 3-week treatment period. The remaining
eight injections were all placebo. Before each injection,
the body weight was measured. The experimenter, whoBMC Biology 2008, 6:37 http://www.biomedcentral.com/1741-7007/6/37
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administered the injections and performed the tests, was
blinded concerning group assignment.
Experimental design of mouse studies
The experimental design including behavioral tests, neu-
rophysiology, and brain tissue analyses is presented in
Figure 1.
Experiment 1
EPO effects on basic behavior and cognition of young
healthy mice after termination of EPO treatment were
assessed. Mice were tested, starting on the day after the last
injection, for anxiety (EPM, elevated plus maze), sponta-
neous loco-motor activity (OF, open field), exploratory
activity (HB, hole board), motor functioning (RR, rota-
rod) and memory (FC, fear conditioning).
Experiments 2 and 3
In these experiments, mice were tested in FC either 3 or 4
weeks after the last EPO injection to explore the duration
of EPO effects on cognition. Hematocrit was determined
immediately after FC.
Experiments 4 and 5
These experiments were set up to obtain brain tissue of
mice for neurophysiology and histology at the time point
with the most prominent effect of EPO on hippocampus
dependent memory.
Behavioral testing
Group size in all behavioral experiments amounted to N
= 15–28. Exact numbers of individual experiments are
given in the legend of Figure 2.
Elevated plus maze
The mouse was placed in the central platform, facing an
open arm of the plus-maze. Behavior was recorded by an
overhead video camera and a PC equipped with 'Viewer'
software (Biobserve, Bonn, Germany) to calculate the
time each animal spends in open or closed arms. The time
spent in open arms was used for estimation of open arm
aversion (fear equivalent).
Open field
Spontaneous activity in open field was tested in a grey Per-
spex arena (120 cm in diameter, 25 cm high). The mouse
was placed in the center and allowed to explore the open
field for 7 min. The behavior was recorded by a PC-linked
overhead video camera. 'Viewer' software was used to cal-
culate velocity, distance traveled and time spent in central,
intermediate or peripheral zones of the open field.
Hole board
The hole board test measures exploratory activity. The
apparatus consisted of a 21 cm × 21 cm × 36 cm transpar-
ent Perspex chamber with a non-transparent floor raised 5
cm above the bottom of the chamber with 12 equally
spaced holes, 2 cm in diameter. Mice were allowed to
explore the chamber for 3 min and the number of
explored holes (head dips) was scored by a trained exper-
imenter.
Rota-rod
Rota-rod is a test for motor function, balance and coordi-
nation and comprises a rotating drum (Ugo Basile, Com-
erio, Varese, Italy), which is accelerated from 4 to 40
revolutions per minute over the course of 5 min. Each
mouse was placed individually on a drum and the latency
of falling from the drum was recorded using a stop-watch.
To assess motor learning, the rota-rod test was repeated 24
h later.
Cued and contextual fear conditioning
The fear conditioning test was performed as described in
detail earlier [23]. Briefly, mice were trained within the
same session for both contextual and cued fear condition-
ing. Training consisted of exposing mice for 120 s to the
context to assess the baseline level of activity. This period
was followed by a 10 s, 5 kHz, 85 dB tone (conditioned
stimulus, CS). Immediately after the tone, a 2 s, 0.4 mA
foot shock (unconditioned stimulus, US) was applied.
This CS-US pairing was repeated 13 s later. All mice
remained in the conditioning chambers for an additional
23 s following the second CS-US pairing. The contextual
memory test was performed 72 h after this training. Mice
were monitored over 2 min for freezing in the same con-
text as used for training. The cued memory test was per-
formed 76 h after training in a new chamber. First, mice
were monitored for freezing over a 2 min pre-cue period
with no tone to assess freezing in the new context. Next, a
2 min cue period followed during which the tone was pre-
sented. Duration of freezing behavior, defined as the
absolute lack of movement (excluding respiratory move-
ments), was recorded by a video camera and a PC
equipped with 'Video Freeze' software (MED Associates,
St. Albans, Vermont, USA).
Brain dissection and sections preparation
For RNA and protein analysis, mice were deeply anaesthe-
tized and decapitated. Hippocampi were taken out,
immediately frozen on dry ice and stored at -80°C. For
histology, mice were perfused under deep anesthesia with
4% paraformaldehyde. Brains were dissected, postfixed
overnight at 4°C and transferred into 30% sucrose/PBS
solution. After having sunk, they were frozen in liquid
nitrogen and stored at -80°C. Whole mouse brains were
cut into 30 μm thick coronal sections on a cryostat (Leica,
Wetzlar, Germany) and kept in a storage solution (25%
ethyleneglycol and 25% glycerol in PBS). Every 10th sec-
tion throughout the dorsal part of the hippocampal for-BMC Biology 2008, 6:37 http://www.biomedcentral.com/1741-7007/6/37
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mation was selected for staining, yielding five to six
sections per brain, used for either volumetrical analysis or
confocal microscopy.
Volumetric measurements using histological sections
The sections were mounted on Super Frost microscopic
slides, washed in phosphate buffer, then immersed for 25
min in a dilute cresyl violet stain (0.01%) in acetate buffer
(pH 4.5), dehydrated in serial dilutions of ethyl alcohol
and finally coverslipped using DePeX (Serva, Heidelberg,
Germany). Calculation of the volume of CA1, CA3 subre-
gions and the total hippocampus was based on thickness
of the sections and areas obtained by tracing contours
around the regions of interest, using a light microscope
(Olympus BX50) modified for stereology with a 10×
objective, a computer-driven motorized stage, Z-axis posi-
tion encoder (microcator), and a microfire video camera
interfaced to a PC with the software Stereo Investigator
6.55 (MicroBrightfield, Inc., Williston, VT, USA). Volu-
metric determinations were performed on both sides of
the hippocampus.
Confocal analysis
For counting of synaptic boutons, sections were washed in
PBS, permeabilized and blocked in 5% blocking serum for
1 h at 4°C, and incubated at 4°C overnight with rabbit
polyclonal synapsin1 antibody (1:4000; Synaptic Sys-
tems, Goettingen, Germany). After PBS washes, the sec-
tions were incubated with anti-rabbit AlexaFluor555-
labeled secondary antibody (1:2000; Invitrogen, Karl-
sruhe, Germany). Following PBS washes, sections were
mounted on Super Frost microscopic slides, air dried and
coverslipped with fluorescence mounting medium (Vec-
tor, Burlingame, CA, USA) containing DAPI. Synapsin1
immunoreactive presynaptic boutons were analysed
within stratum radiatum of area CA1 and stratum luci-
dum of area CA3 of hippocampus. Images were obtained
at a zoom factor 4 using an inverted confocal laser scan-
ning microscope (LSM 510; Zeiss, Goettingen, Germany)
with a 63× oil-immersion objective. For intensity compar-
isons, gain and offset were held constant across images.
Synapsin1 immunoreactive punctae were quantified
using ImageJ software (Rasband, W.S., ImageJ, U. S.
National Institutes of Health, Bethesda, Maryland, USA).
Images were manually thresholded and particle analysis
plugin was used to calculate the number of immunoreac-
tive punctae.
Hippocampal slice preparation and solution
Acute hippocampal slices were prepared from 56 days old
mice (Figure 1, Exp. 4). As in all experiments performed
here, the experimenter was blinded regarding group
assignment. Mice were deeply anesthetized with diethyl
ether before decapitation. The brain was quickly removed
and immersed for 2–3 min in ice-cold artificial cerebros-
pinal fluid (ACSF). The ACSF had the following composi-
tion (in mM): 130 NaCl, 3.5 KCl, 1 CaCl2, 1.2 MgSO4, 24
NaHCO3, 1.25 NaH2PO4, 10 Glucose, with the pH
adjusted to 7.4. Transverse slices of 400 μm thickness were
cut with a vibroslicer (752 M, Campden Instruments,
Loughborough, UK). The slices were then transferred to
an interface recording chamber of the Oslo type and
allowed to recover for at least 90 min. The recording
chamber was continuously perfused with ACSF, aerated
with 95% O2 and 5% CO2 (3–4 ml/min). The temperature
was kept at 34°C.
Extracellular recordings of hippocampal slices
The recording electrodes were pulled from thin-walled
borosilicate glass capillaries (GC150TF-10, Harvard
Apparatus, Holliston, MA, USA) using a horizontal
Flaming-Brown micropipette puller (P-80/PC, Sutter
Instrument Co., Novato, CA, USA). They were filled with
ACSF. Monopolar stimulation electrodes made from
bare stainless steel microwire (50 μm diameter, AM-Sys-
tems) were used for stimulation. The stimuli were gener-
ated by photoelectric stimulus isolation units (Grass
PSIU6) triggered by a stimulator (Grass S88). Extracellu-
lar field potential recordings were done using a custom-
built DC amplifier. Data were digitized by a DigiData
1322A (Molecular Devices, Sunnyvale, CA, USA). Initial
analysis of the data was done in Clampfit 9.0 (Molecular
Devices, Sunnyvale, CA, USA). To evoke field excitatory
postsynaptic potentials (fEPSPs), the stimulation elec-
trode was placed in stratum radiatum at CA3/CA1 junc-
tion for the activation of Schaffer collaterals. The
recording electrode was placed in the stratum radiatum
of the CA1 region. The magnitude of fEPSPs was meas-
ured as amplitude (baseline to peak) and slope (20–80%
level of the falling phase). For input-output relationship,
fEPSPs were evoked with 0.1 ms stimuli at 0.25 Hz and
an average of four consecutive responses was taken.
fEPSP amplitudes and slopes were plotted against the
stimulus intensity (10 to 150 μA). Paired-pulse facilita-
tion (PPF) was measured at different interstimulus inter-
vals (25, 50, 75, 100, 125, 150, 175 and 200 ms) as the
ratio of the second fEPSP to the first fEPSP. Here also the
paired stimuli were given at 0.25 Hz and an average of
four consecutive responses was taken. To study long-
term potentiation (LTP), baseline responses were evoked
every 20 s for 5 min and LTP was induced by three trains
separated by 20 s, each train consisting of 100 Hz stimu-
lation for 1s. The post-train responses were then meas-
ured every 20 s for 60 min. The magnitude of LTP was
measured as the average of responses between 50 and 60
min after induction. To study long-term depression
(LTD), baseline responses were evoked every 15 s for 5
min and LTD was induced by 900 stimuli delivered at 1
Hz. The post-train responses were then measured every
15 s for 60 min. The magnitude of LTD was measured as
the average of responses between 50 and 60 min after
induction.BMC Biology 2008, 6:37 http://www.biomedcentral.com/1741-7007/6/37
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Whole-cell patch clamp-recordings
Acute transverse 300 μm hippocampal slices were pre-
pared as described above. After preparation, slices were
incubated for 30 min at 34°C, followed by room temper-
ature incubation for more than 1 h. All recordings were
performed in CA1 hippocampal pyramidal neurons. The
extracellular solution in all experiments was the same as
the one used in LTP experiments. The pipette solution for
all experiments contained (in mM): 140 KCl, 1 CaCl2, 10
EGTA, 2 MgCl2, 4 Na3ATP, 0.5 Na3GTP, 10 HEPES at pH
7.3. Spontaneous inhibitory PSCs were recorded at a Cl-
reversal potential of about 0 mV in 10 μM CNQX and 40
μM AP5. Spontaneous excitatory PSCs were recorded in
the presence of 1 μM strychnine and 1 μM bicuculline.
Signals with amplitudes of at least two times above the
background noise were selected. Patches with a serial
resistance of > 10 MΩ, a membrane resistance of < 0.2 GΩ,
or leak currents of > 200 pA were excluded. The mem-
brane currents were filtered by a four-pole Bessel filter at a
corner frequency of 2 kHz, and digitized at a sampling rate
of 5 kHz using the DigiData 1322A interface (Molecular
Devices, Sunnyvale, CA). Data acquisition and analysis
were done using commercially available software:
pClamp 9.0 (Molecular Devices, Sunnyvale, CA), MiniA-
nalysis (SynaptoSoft, Decatur, GA) and Prism 4 (Graph-
Pad Software, San Diego, CA).
Primary hippocampal neuronal culture
Mice at embryonic day 17 (E17) were used for preparation
of hippocampal primary neuronal cell cultures [24,25]
Briefly, after complete removal of meninges, hippocampi
were dissected in warm HBSS solution (Invitrogen, Karl-
sruhe, Germany), supplemented with penicillin and
streptomycin, and trypsinized. After mechanical tritura-
tion with fire polished Pasteur pipettes, cells were plated
on poly-D-lysine- and laminin-coated 6-well plates (for
Western blotting and quantitative RT PCR) or on poly-D-
lysine- and laminin-coated MEA dishes (for multi-elec-
trode array, MEA) or on poly-D-lysine- and laminin-
coated glass cover slips in 6-well plates (for immunocyto-
chemistry) at a density of 200000 cells per well. Neurons
were cultured in MEM/B27 medium (Invitrogen, Karl-
sruhe, Germany) supplemented with sodium bicarbo-
nate, sodium pyruvate, L-glutamine, penicillin,
streptomycin and 0.6% glucose. Cultures were incubated
at 37°C under 7.5% CO2/92.5% air and 90% humidity.
One-third of medium volume was exchanged every 5th
day. Contamination with glial fibrillary acidic protein
positive astrocytes on day 5 in culture was consistently less
than 7%. For all MEA experiments, EPO or control treat-
ment (0.3 IU/ml = 10-10 M) was started on day 5 and con-
tinued by addition of EPO every other day until day 25.
Cell cultures were maintained until day 50 for MEA, until
day 8, 14, or 30 for Western blotting and quantitative RT
PCR, until day 10 and 30 for immunocytochemistry.
Immunostaining of cultured cells
After 10 or 30 days in culture, cells were washed in PBS,
fixed with 4% paraformaldehyde in PBS, permeabilized
and blocked in 0.2% Triton X-100/PBS with 10% block-
ing serum, and incubated at 4°C overnight with mouse
monoclonal MAP-2 (1:500; Chemicon, Hampshire, UK)
or mouse monoclonal GFAP (1:500; Novocastra, Newcas-
tle Upon Tyne, UK) antibodies diluted in 1% blocking
serum/PBS. After PBS washes, the cells were incubated
with Cy2-labeled secondary antibody (1:250; Jackson
ImmunoResearch, Newmarket, UK), washed in PBS, air
dried and coverslipped with fluorescence mounting
medium (Vector, Burlingame, CA, USA) containing pro-
pidium iodide.
Multi-electrode array recordings and analysis
For determination of spontaneous electrical network
activity in primary mouse hippocampal neuronal cul-
tures, we used multi-electrode arrays (MEA) of 60 tita-
nium nitride electrodes with 30 μm diameter each and
200 μm inter-electrode distance (Multi Channel Systems,
Germany). Raw data from the MEA electrodes were ampli-
fied by MEA 1060 filter amplifiers (bandwidth 3 Hz-10
kHz; gain × 1100). Sampling frequency amounted to 25
kHz. The experiments were performed at 37°C, using a
TC01 temperature controller. Recording of spontaneous
network activity was carried out daily in the morning for
2 min, starting on day 14 and ending on day 50. This gave
us five weeks of daily recordings, from week 3 until week
7 (total of 37 days). The choice of morning hours for
measurements did not affect the statistics, as confirmed by
an additional evening experiment showing little daily dif-
ferences. Seven independent "sister" cultures (i.e. cultures
derived from the same brain preparation), treated with
EPO or control were analysed. Spike extraction from the
continuous data is commonly achieved by spike sorting
[26,27]. Having to process 481 2 min recordings, manual
interaction, often used to improve sorting behavior, was
not feasible. Thus, automated spike extraction using
MEATools, a MATLAB-based toolbox for comprehensive
analysis of multi-neuronal data http://material.brain
works.uni-freiburg.de/research/meatools/ was employed.
For each channel, principal components were calculated,
and spikes were identified via thresholds in the principal
component contributions. In order to identify multivari-
ate features explaining potential modifications by EPO in
the cell cultures, single sample analyses were performed
first (see Additional file 1). Due to a relatively high back-
ground noise and a low overall number of spikes in the
channels, standard statistics, such as spike rates and spike
time interval distributions, did not capture significant dif-
ferences in EPO versus control cultures (see Additional
files 2 and 3). A direct quantification of the variations in
bursting and silent channels was therefore necessary. Sim-
ilar clustering effects have been previously studied inBMC Biology 2008, 6:37 http://www.biomedcentral.com/1741-7007/6/37
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oscillator networks on a theoretical level [28,29]. Here,
two indices were calculated: (1) In order to measure
silencing in the groups, we determined the number of
channels ci(t) of dish i at time t with basically no spikes
(less than five spikes per 2 min). We then took the mean
of ci(t) over each week and compared the time evolution
of this mean channel activity using a Wilcoxon rank sum
test in each week. The test was performed on the samples
after outlier removal, where an outlier was defined as a
sample not lying within 1.5 times the interquartile range
from the median. (2) In addition to silencing effects, we
analysed bursting behavior. For this, we calculated the
coefficient of variation (CV) of the spike-time interval dis-
tribution in each channel, i.e. the ratio of standard devia-
tion and mean. This measure of dispersion is larger than
1 for hyper-exponential distributions and lower than 1 for
lower-variance distributions. In the case of bursting chan-
nels, over-proportionally many small spike-time intervals
were observed, so the spike-time intervals obeyed a hyper-
exponential distribution, which could be identified by
high CV-values of the corresponding channels. We
defined bursting behavior if the CV-value was above 1,
and strongly bursting behavior if it was above a threshold
of 2.6 (see also Additional file 1). In order to quantify
bursting over all channels, we counted the percentage bi(t)
of strongly bursting channels of all active channels of dish
i at time t. By calculating relative bursting with respect to
active channels, we were able to study bursting independ-
ent of the number of silent channels. Again, we took the
mean over each week, and tested for differing medians of
the EPO and the control group using a rank sum test.
Autaptic neuron experiments
Cell culture
Microislands of astrocyte feeder cells were prepared two
days before plating hippocampal neurons [30]. Islands of
substrate (10 mM acetic acid, 0.1 mg/ml poly-D-lysine,
and 0.2 mg/ml collagen) were applied to agarose-coated
glass coverslips using a stamp containing regularly spaced
squares (200 μm × 200 μm). To obtain astrocytes and hip-
pocampal neurons, P0 mice were decapitated, and brains
were removed and cleaned of meninges and vascular tis-
sue. To obtain hippocampal neurons, hippocampi were
removed in HBSS, digested in papain (25 IU/ml, Wor-
thington Biomedical) in DMEM (supplemented with 1
mM CaCl2, 0.5 mM EDTA, and 1.65 mM L-cysteine) for
45 min at 37°C, incubated for 15 min at 37°C in serum-
free medium (Neurobasal medium A supplemented with
2.5 mg/ml Albumin and 2.5 mg/ml Trypsin inhibitor)
and dissociated. To obtain astrocytes, the cortices of sepa-
rate animals were removed in HBSS, similarly dissociated
(digested for 15 min at 37°C in Trypsin/EDTA) and plated
at a density of 2500 per cm2 in DMEM containing 10%
fetal calf serum, penicillin/streptomycin, and MITO (Bec-
ton Dickinson). Before plating the dissociated hippocam-
pal neurons at a density of 300 per cm2, the medium of
the astrocyte feeder cells was replaced with Neurobasal
medium A (supplemented with B27, Glutamax-I and pen-
icillin/streptomycin). Neurons were allowed to mature
until days 9, 11, or 14 to be used for electrophysiology or
immunocytochemistry. Only islands containing single
neurons were examined. EPO versus control (diluent
solution) treatment was performed on day 7. If not other-
wise indicated, cell culture reagents were obtained from
GIBCO/Invitrogen.
Immunostaining
For estimating the number of synaptic boutons in autaptic
neurons, cells were washed in PBS, fixed with 4% parafor-
maldehyde in PBS, permeabilized and blocked in 0.2%
Triton X-100/PBS with 10% blocking serum, and incu-
bated at 4°C overnight with mouse monoclonal
synapsin1 antibody (1:1000 SynapticSystems, Goettin-
gen, Germany) diluted in 1% blocking serum/PBS. After
PBS washes, cells were incubated with Cy3-labeled sec-
ondary antibody (1:1000; Jackson ImmunoResearch,
Newmarket, UK), washed in PBS and incubated at 4°C
overnight with mouse monoclonal MAP-2 (1:500;
Chemicon, Hampshire, USA) antibody. Following PBS
washes, the cells were incubated with Cy2-labeled second-
ary antibody (1:250; Jackson ImmunoResearch, Newmar-
ket, UK), washed in PBS, air dried and coverslipped with
fluorescence mounting medium (Vector, Burlingame, CA,
USA) containing DAPI. Images of individual neurons
were captured using an upright epifluorescence Olympus
BX61 microscope (Hamburg, Germany) with a 40× oil-
immersion objective. Images were photomerged to recon-
struct individual neurons using Adobe Photoshop CS3
software. The number of synapsin1 immunoreactive
punctae of 18–20 neurons per coverslip (six coverslips per
condition) were quantified using ImageJ software with
manual thresholding and particle analysis plugin. Estima-
tion of the percentage of excitatory and inhibitory neu-
rons was performed by visual distinction between the
degree of arborization, thickness of processes and shape
of soma. Amount of inhibitory neurons among the total
neuronal population was found to be 10–20% per cul-
ture.
Electrophysiology
Cells were whole-cell voltage clamped at -70 mV with
pClamp10 amplifier. All analyses were performed using
Axograph 4.9 (Molecular Devices, Sunnyvale, CA, USA).
The size of the readily releasable pool (RRP) of synaptic
vesicles was determined by a 6 s application of the exter-
nal saline solution made hypertonic by the addition of 0.5
M sucrose. Recordings of mEPSCs were performed in the
presence of 300 nM tetrodotoxin (TTX). EPSCs were
evoked by depolarizing the cell from -70 to 0 mV for 2 ms.
The effect of high-frequency stimulation on the amplitudeBMC Biology 2008, 6:37 http://www.biomedcentral.com/1741-7007/6/37
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of EPSCs was measured by applying depolarisations at a
frequency of 10 Hz for 50 stimuli. To measure NMDA/
AMPA ratio, EPSCs were stimulated in the presence of 10
mM glycine, 2.5 mM Ca2+ (no Mg2+) to activate the synap-
tic NMDA receptors in hippocampal autaptic culture. The
evoked EPSCs had a fast AMPA component followed by a
slow NMDA component. To examine the changes in syn-
aptic NMDA/AMPA ratios in presence and absence of
EPO, the NMDA components relative to the AMPA com-
ponent were measured.
Patch-pipette solutions contained (mM): 146 potassium
gluconate, 18 HEPES, 1 EGTA, 4.6 MgCl2, 4 NaATP, 0.3
Na2GTP, 15 creatine phosphate and 5 U/ml phosphocre-
atine kinase (315–320 mOsmol/l, pH 7.3). The extracel-
lular saline solution contained (mM): 140 NaCl, 2.4 KCl,
10 HEPES, 10 glucose, 4 CaCl2 and 4 MgCl2 (320 mOs-
mol/l, pH 7.3). All chemicals, except for TTX (Tocris
Cookson) and calcimycin (Calbiochem) were purchased
from Sigma. All solutions were applied using a fast-flow
system (Warner Instruments, Hamden, CT, USA) with
custom made flow pipes.
Protein extraction and immunoblot analysis
Tissue samples or cells were lysed with lysis buffer [50 mM
Tris HCL (pH 8.3), 150 mM NaCl, 40 mM NaF, 5 mM
EDTA, 5 mM EGTA, 1 mM Na3VO4, 1% Igepal, 0.1%
Natriumdesoxycholat, 0.1% SDS] containing 1 mM Phe-
nylmethysulfonylfluoride, 10 μg/ml Aprotinin and 1 mg/
ml Leupeptin. The lysates were freeze-thawed four times
and homogenized by pulling through a 1 ml syringe 10
times, transferred into microcentrifuge tubes and centri-
fuged (1200 rpm) at 4°C for 45 min. The supernatant was
mixed with three volumes of Laemmli buffer [250 mM
Tris HCL (pH 8.3), 8% SDS, 40% glycerol, 20% 2-mercap-
toethanol, 0.04% pyronin Y], boiled for 5 min at 95°C
and frozen at -20°C until blotting. The protein samples
were run on NuPAGE 4–12% Bis-Tris Gel (Invitrogen,
Karlsruhe, Germany) for 35 min at 200 V and transferred
to a nitrocellulose membrane. The blots were blocked
with 2% ECL Advance blocking agent (Amersham,
Freiburg, Germany) in Tween 20-Tris-buffered saline
(TTBS) at room temperature for 1 h and incubated at 4°C
overnight with primary antibody for synapsin1 (1:10000;
Synaptic Systems, Goettingen, Germany) or synapto-
physin (1:500; Sigma, Germany) or α-tubulin as an inter-
nal control (1:5000; Sigma, Germany). Immunoreactive
bands were visualized by using secondary antibodies cou-
pled to horseradish peroxidase by enhanced chemolumi-
nescence (Amersham, Freiburg, Germany). Densitometric
analysis of the protein bands was performed by using
ImageJ software.
RNA isolation and expression analysis by quantitative real-
time RT-PCR
RNA was isolated from tissue samples or cells by using the
RNeasyPlus kit (Qiagen, Hilden, Germany). First strand
cDNA was generated from total RNA using N9 random
and Oligo(dT)18 primers. The relative concentrations of
mRNAs of interest in different cDNA samples were meas-
ured out of four replicates using the threshold cycle
method (Ct) for each dilution and were normalized to
levels of murine 18S RNA. Reactions were performed
using SYBR green PCR master mix (ABgene, Foster City,
CA, USA) according to the protocol of the manufacturer.
Cycling was done for 2 min at 50°C, followed by denatur-
ation at 95°C for 10 min. The amplification was carried
out by 45 cycles of 95°C for 15 s and 60°C for 60 s. The
specificity of each primer pair was controlled with a melt-
ing curve analysis. Quantitative RT-PCR was performed
with primers listed below:
NM_007540.3 Mus musculus brain derived neurotrophic fac-
tor (BDNF), mRNA
mouse BDNF fwd: GCA TCT GTT GGG GAG ACA AG
mouse BDNF rev: TGG TCA TCA CTC TTC TCA CCT G
NM_010149.2  Mus musculus erythropoietin receptor
(EPOR), mRNA
mouse EPOR fwd: CCT CAT CTC GTT GTT GCT GA
mouse EPOR rev: CAG GCC AGA TCT TCT GCT G
NM_009305.1 Mus musculus synaptophysin (Syp), mRNA
mouse synaptophysin fwd: CAA GGC TAC GGC CAA CAG
mouse synaptophysin rev: GGT CTT CGT GGG CTT CAC T
NM_013680.3 Mus musculus synapsin1 (Syn1), mRNA
mouse synapsin1 fwd: GGA AGG GAT CAC ATT ATT GAG
G
mouse synapsin1 rev: TGC TTG TCT TCA TCC TGG TG
Statistical analysis
Statistical significance was evaluated using two-tailed
unpaired Student's t-test, with or without Welch's correc-
tion, depending on the distribution of the data (tested
with a Kolmogorov-Smirnov test). Significance level was
set to P < 0.05. Numerical values are represented as meanBMC Biology 2008, 6:37 http://www.biomedcentral.com/1741-7007/6/37
Page 15 of 16
(page number not for citation purposes)
± S.E.M. in Figures and text. Plotting of the data as well as
statistical analyses were done in Prism 4 (GraphPad Soft-
ware, San Diego, CA, USA) and MATLAB 7 (The Math-
Works, Natick, MA, USA).
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